Acetamidoxolutamide; Androxolutamide; GTx-007; S-4
(2 S)-3-(4-acetamido-phenoxy)-2-hydroxy-2-methyl- N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide
Chemical and physical data
C 19 H 18 F 3 N 3 O 6
Molar mass 441.357 g/mol
3D model (
(what is this?) (verify)
Andarine ( GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the  nonsteroidal antiandrogen bicalutamide as a lead compound. 
Andarine is an orally active
partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. This suggests that it is able to competitively block binding of  dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH. 
See also [ edit ]
References [ edit ]
^ Hott JL, Borkman RF (November 1989). "The non-fluorescence of 4-fluorotryptophan". The Biochemical Journal. 264 (1): 297–9. doi: 10.1124/jpet.102.040840. PMC . 1133577 PMID 2604714.
^ Chen J, Kim J, Dalton JT (June 2005). "Discovery and therapeutic promise of selective androgen receptor modulators". Molecular Interventions. 5 (3): 173–88. doi: 10.1124/mi.5.3.7. PMC . 2072877 PMID 15994457.
^ G Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT (December 2004). "Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia". Endocrinology. 145 (12): 5420–8. doi: 10.1210/en.2004-0627. PMC . 2098692 PMID 15308613.
^ Gao W, Kim J, Dalton JT (August 2006). "Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharmaceutical Research. 23 (8): 1641–58. doi: 10.1007/s11095-006-9024-3. PMC . 2072875 PMID 16841196.